Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

87.92 +0.65 (+0.74%)

Streaming Delayed Price Updated: 1:34 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

3 Reasons to Avoid GH and 1 Stock to Buy Instead

Today 0:06 EDT

What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 46.9%, hitting $86.90. This was partly thanks to its solid ...

Via StockStory

Topics Supply Chain

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

March 18, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

March 16, 2026

From Guardant Health, Inc.

Via Business Wire

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

Via The Motley Fool

Topics Regulatory Compliance

Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗

February 19, 2026

Via Chartmill

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.

Via The Motley Fool

Topics Regulatory Compliance

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

March 13, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

March 10, 2026

From Guardant Health, Inc.

Via Business Wire

1 Russell 2000 Stock on Our Watchlist and 2 We Question

March 05, 2026

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Via StockStory

Topics Supply Chain

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

March 04, 2026

From Guardant Health, Inc.

Via Business Wire

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

March 03, 2026

From Guardant Health, Inc.

Via Business Wire

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

Via StockStory

Topics Economy Stocks

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2026

From Guardant Health, Inc.

Via Business Wire

The Great Rotation: Small-Caps Break Record Highs as the 'Catch-Up' Trade Ignites

February 26, 2026

In a dramatic shift that has caught Wall Street’s heavy hitters off guard, the Russell 2000 index has surged to unprecedented heights in early 2026, signaling the definitive arrival of the long-awaited...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

February 23, 2026

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...

Via StockStory

Topics Economy Government World Trade

Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

February 19, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 39.4% year on year to $281.3 million. The company’s full-year revenue...

Via StockStory

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

February 19, 2026

From Guardant Health, Inc.

Via Business Wire

Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow

February 17, 2026

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence Economy World Trade

3 Unprofitable Stocks Walking a Fine Line

February 15, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...

Via MarketMinute

Topics Bonds ETFs Economy

Guardant Health to Participate in Upcoming Investor Conferences

February 03, 2026

From Guardant Health, Inc.

Via Business Wire

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

February 02, 2026

From Guardant Health, Inc.

Via Business Wire

3 Unpopular Stocks We Think Twice About

February 01, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

This genomics stock appears to be at an inflection point.

Via The Motley Fool

Topics Earnings

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

January 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 22, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 19, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group

January 14, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.

Via StockStory

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.